Glycopyrrolate prophylaxis may not obviate Vasopressor need for hypotension in non-elective cesarean

Written By :  Dr.Niharika Harsha B
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-12-08 14:30 GMT   |   Update On 2022-12-08 14:31 GMT

A new trial found that glycopyrrolate prophylaxis for preventing hypotension could not reduce the necessity of vasopressor in the non-elective cesarean section under spinal anesthesia. The trial results were published in the journal BMC Anesthesiology. Spinal Anesthesia is frequently used during cesareans, but hypotension may result following it which may adversely affect the neonate....

Login or Register to read the full article

A new trial found that glycopyrrolate prophylaxis for preventing hypotension could not reduce the necessity of vasopressor in the non-elective cesarean section under spinal anesthesia.

The trial results were published in the journal BMC Anesthesiology.  

Spinal Anesthesia is frequently used during cesareans, but hypotension may result following it which may adversely affect the neonate. As literature shows that glycopyrrolate increases maternal heart rate, researchers conducted a trial to determine if prophylactic use of glycopyrrolate decreases the vasopressor requirements to prevent hypotension following spinal anesthesia during non-elective cesarean section. 

A double-blind randomized clinical trial was done on 258 patients undergoing non-elective cesarean section. They were randomly assigned (1:1) to receive intravenous 0.2 mg glycopyrrolate or normal saline (placebo) before spinal anesthesia. The primary outcome was the phenylephrine equivalent needed intraoperatively. Secondary outcomes included incidences of maternal hypotension, reactive hypertension, bradycardia, need for atropine, tachycardia, intraoperative nausea/vomiting, shivering, pruritus, dry mouth, dizziness; neonatal APGAR score at 1 min and 5 min, neonatal resuscitation needed, NICU admission and neonatal death.

Results: 

255 participants were analyzed as 3 patients withdrew from the study due to failed spinal anesthesia.

The mean difference of phenylephrine equivalent between the two groups was 5.32 μg.

Hypotension and Tachycardia were reported in both groups. 

No statistically significant difference was noted in hypotensive episodes > 1, reactive hypertension, bradycardia, need for atropine, nausea, vomiting, shivering, and dry mouth between the two groups.

Neonatal outcomes were similar in the two groups. 


Glycopyrrolate groupPlacebo group
No. of patients128127

mean phenylephrine equivalent

1108.96 μg

1103.64 μg

Hypotension

38 patients (30%) 

49 patients (39%)

Tachycardia 

70%

 57% 


Thus, the necessity of a vasopressor to prevent hypotension could not be reduced by the prophylactic use of glycopyrrolate in the non-elective cesarean section under spinal anesthesia. 

Further reading: Deshar, R., Subedi, A., Pokharel, K. et al. Effect of glycopyrrolate on vasopressor requirements for non-elective cesarean section under spinal anesthesia: a randomized, double-blind, placebo-controlled trial. BMC Anesthesiol 22, 327 (2022). https://doi.org/10.1186/s12871-022-01882-4

Tags:    
Article Source : BMC Anesthesiology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News